Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

In the current study, all patients who initially received placebo were switched to a daily dose of 15 mg of upadacitinib, matching the dosage of the treated group. Among patients who received ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

The efficacy and safety of withdrawing versus continuing upadacitinib in maintaining remission ... CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract ...

1 In this trial, primary and key secondary endpoints were achieved with RINVOQ 15 mg and a 26-week steroid taper regimen compared to placebo in combination with a 52-week steroid taper regimen.